The global celiac disease market is anticipated to grow significantly at a CAGR of 8.5% during the forecast period (2021-2027). The major players across the globe are adopting different business strategies including expanding their technological advancements, geographic presence, R&D activities, new product approvals, mergers & acquisitions, partnerships, and collaborations to increase market share. Among these, technological advancements, clinical trials for drug development, and others are one of the major factors that are propelling the growth of the market.
(Get 15% Discount on Buying this Report)
Get Report Sample Copy @ https://www.omrglobal.com/request-sample/celiac-disease-market
For instance, in March 2021, ImmunogenX has announced that the CeliacShield trial was completed successfully. Histology, symptoms, serology, and gluten in urine were all assessed in this gluten challenge study. The company’s CypCel diagnostic technology was also used in the experiment as a tiny intestine villous health monitor, with the medication biomarker simvastatin assessed in blood samples. in February 2020, ImmunogenX, a biotherapeutics company, has begun enrolling patients in a Phase IIb clinical trial using Latiglutenase (IMGX003) for celiac disease treatment. IMGX003 is a drink-based experimental drug that helps patients improve their quality of life by breaking down gluten in the stomach and reducing gluten-induced symptoms.
A Full Report of Global Celiac Disease Market is Available at: https://www.omrglobal.com/industry-reports/celiac-disease-market
Besides, in September 2020, Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced today that its exclusive global collaboration agreement with Bristol Myers Squibb, a company focused on developing autoimmune disease therapeutics, has been expanded to include Anokion’s lead antigen-specific drug candidate, KAN-101, for the treatment of celiac disease. Apart from it, in September 2019, GlaxoSmithKline has acquired Sitari Pharmaceuticals, the first company created through its collaboration with Avalon Ventures. Inhibitors of the TG2 enzyme are being developed by a preclinical-stage biotech company named Sitari Pharmaceuticals as therapies for celiac disease, an autoimmune digestive illness. The interest in TG2 by Sitari and GSK is based on data that the protein’s enzymatic activity begins the inflammatory cascade that drives and defines the disease. Gluten, a protein present in wheat, rye, and barley, causes gastrointestinal damage and decreased nutritional absorption, which precludes celiac disease sufferers from ingesting gluten-containing foods. Thus, the major player’s focus on the treatment of celiac disease is driving the growth of the global celiac disease market during the forecast period.
Global Celiac Disease Market Report Segment
By Treatment Type
- Vitamins and Dietary (Gluten-Free) Supplements
- Steroids and Immunosuppressive Drugs
- Therapeutic Vaccines
By Diagnostic Type
- Serologic Test
- Genetic Testing
- Small-Bowel Biopsy
By End-User
- Hospitals and Diagnostics Centers
- Research Institutes
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
